Business Context and Reporting Period
Company: UPEXI, INC. (UPXI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2024
Business Overview: Upexi is a brand owner specializing in the development, manufacturing, and distribution of consumer products, including pet care (LuckyTail), health and wellness (Cure Mushrooms, Moonwlkr), and energy solutions (PRAX). The company operates through direct-to-consumer channels, wholesale partnerships, and third-party platforms like Amazon. During the fiscal year, the company significantly restructured its portfolio, divesting several subsidiaries (VitaMedica, E-Core, Interactive Offers) and consolidating manufacturing operations to Florida.
Key Financial Metrics
| Metric | Fiscal Year 2024 | Fiscal Year 2023 |
|---|---|---|
| Revenue | $26,000,652 | $36,441,695 |
| Gross Profit | $12,824,579 | $21,019,980 |
| Gross Margin | 49.32% | 57.68% |
| Net Loss (Attributable to Upexi) | $(23,658,438) | $(16,930,289) |
| Operating Cash Flow (Continuing Ops) | $(4,894,751) | $(7,421,529) |
| Cash and Equivalents (End of Period) | $661,415 | $4,492,292 |
| Working Capital | $(1,235,234) | $7,621,397 |
| Total Debt (Notes Payable & Convertible) | $10,689,532 | $25,889,239 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 29% ($10.4 million) primarily due to a 42% drop in product sales through third-party channels (Amazon) and the exit of the recommerce strategy. This was partially offset by $5 million in manufacturing sales.
- Margin Compression: Gross margin declined by 8.36 percentage points. This was driven by a $3.0 million inventory write-off and increased reserves related to the strategic consolidation of operations to Florida and the elimination of the recommerce business.
- Impairments: The company recorded $7.9 million in impairment of intangible assets and goodwill. This included $6.8 million related to the Cygnet acquisition (exiting recommerce) and $975,000 related to LuckyTail (decline in direct-to-consumer sales).
- Divestitures: The company sold VitaMedica (gain of $1.9 million) and E-Core (loss of $1.7 million). These operations are now classified as discontinued operations.
- Liquidity Position: Working capital turned negative from a surplus of $7.6 million in 2023 to a deficit of $1.2 million in 2024. Cash on hand decreased by $3.8 million.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management expects gross margins to improve following the strategic shift to focus on branded product sales and the completion of manufacturing consolidation in Florida (full capacity achieved August 2024). The company anticipates general and administrative expenses will decline in the coming quarters. Management intends to finance operations over the next 12 months using existing cash, cash flow from operations, proceeds from the VitaMedica sale, and potential short-term debt financing.
Key Risks & Contingencies:
- Legal Proceedings: The company is defending two significant lawsuits involving its subsidiary Cygnet Online, LLC. Umpqua Bank alleges a default on a loan totaling approximately $3.8 million. Get Fit Fast Supplements, LLC claims damages of approximately $3.1 million related to an asset purchase agreement.
- Regulatory Environment: Operations involving hemp and CBD products face evolving federal (FDA) and state regulations. The FDA has taken the position that CBD is prohibited in food and dietary supplements, creating uncertainty for product lines.
- Internal Controls: Management concluded that internal control over financial reporting was not effective as of June 30, 2024, citing material weaknesses in segregation of duties and lack of multiple levels of supervision.
- Going Concern: While management believes it has sufficient working capital for the next 12 months, the company's ability to continue as a going concern depends on generating profitable operations or obtaining necessary financing.
Investor Verification Checklist
- Legal Exposure: Verify the status and potential financial impact of the pending litigation against Cygnet Online (Umpqua Bank and Get Fit Fast Supplements cases).
- Inventory Valuation: Review the $3.0 million inventory write-off and the remaining inventory reserves ($605,470) to assess the risk of future obsolescence charges.
- Debt Covenants: Examine the terms of the $10.7 million in outstanding debt, particularly the mortgage on the Clearwater building (sold July 2024) and the related party note with the CEO, to ensure compliance with covenants.
- Regulatory Compliance: Assess the impact of FDA guidance on CBD ingredients on the company's core product lines (Moonwlkr, Cure Mushrooms).
- Internal Controls: Monitor the remediation plan for material weaknesses in internal controls, specifically regarding segregation of duties and financial reporting review processes.